Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations
Sheikh Bilal Ahmad, Maria Batool, Quratul Ain, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9124-9124
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
Mahrokh Marzi, Mohammad Kazem Vakil, Maryam Bahmanyar, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-16
Open Access | Times Cited: 103
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
Yuan‐Pin Hung, Jen‐Chieh Lee, Chun-Wei Chiu, et al.
Antibiotics (2022) Vol. 11, Iss. 2, pp. 220-220
Open Access | Times Cited: 89
Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19)
Terry Cheuk‐Fung Yip, Grace Lui, Mandy Sze-Man Lai, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e26-e33
Open Access | Times Cited: 84
Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
Zongyang Lv, Kristin E. Cano, Lijia Jia, et al.
Frontiers in Chemistry (2022) Vol. 9
Open Access | Times Cited: 75
The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
Nancy H.C. Loos, Jos H. Beijnen, Alfred H. Schinkel
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9866-9866
Open Access | Times Cited: 69
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
Nur Zawanah Zabidi, Hern Liang Liew, Isra Ahmad Farouk, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 944-944
Open Access | Times Cited: 59
Highly sensitive high‐performance thin‐layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations
Roshdy E. Saraya, Sami El Deeb, Baher I. Salman, et al.
Journal of Separation Science (2022) Vol. 45, Iss. 14, pp. 2582-2590
Closed Access | Times Cited: 65
Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
János András Mótyán, Mohamed Mahdi, Gyula Hoffka, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3507-3507
Open Access | Times Cited: 61
Halogenated Baicalein as a Promising Antiviral Agent toward SARS-CoV-2 Main Protease
Kowit Hengphasatporn, Patcharin Wilasluck, Peerapon Deetanya, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 6, pp. 1498-1509
Closed Access | Times Cited: 55
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
Karolina Akinosoglou, Georgios Schinas, Charalambos Gogos
Viruses (2022) Vol. 14, Iss. 11, pp. 2540-2540
Open Access | Times Cited: 53
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
Nada A. Ashour, Ayman Abo Elmaaty, Amany A. Sarhan, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 685-715
Open Access | Times Cited: 40
Comparative evaluation of authorized drugs for treating Covid‐19 patients
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, et al.
Health Science Reports (2022) Vol. 5, Iss. 4
Open Access | Times Cited: 38
Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
Marina Macchiagodena, Marco Pagliai, Piero Procacci
Journal of Molecular Graphics and Modelling (2021) Vol. 110, pp. 108042-108042
Open Access | Times Cited: 41
Ligand-based design, synthesis, computational insights, andin vitrostudies of novelN-(5-Nitrothiazol-2-yl)-carboxamido derivatives as potent inhibitors of SARS-CoV-2 main protease
Mohamed Elagawany, Ayman Abo Elmaaty, Ahmed Mostafa, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 2112-2132
Open Access | Times Cited: 35
Structure-based 3D-Pharmacophore modeling to discover novel interleukin 6 inhibitors: An in silico screening, molecular dynamics simulations and binding free energy calculations
Que-Huong Tran, Quoc‐Thai Nguyen, Nguyen-Quynh-Huong Vo, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0266632-e0266632
Open Access | Times Cited: 33
Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy
Harry Ridgway, Christos T. Chasapis, Konstantinos Kelaidonis, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 1029-1029
Open Access | Times Cited: 33
Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC–MS/MS and its pharmacokinetic application in healthy Chinese volunteers
Chenxi Liu, Miqun Zhu, Liyun Cao, et al.
Biomedical Chromatography (2022) Vol. 36, Iss. 11
Closed Access | Times Cited: 32
Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity
Mohamed Haddad, Roger Gaudreault, Gabriel Sasseville, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2643-2643
Open Access | Times Cited: 31
Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2
Harry Ridgway, Graham J. Moore, Thomas Mavromoustakos, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 2091-2111
Open Access | Times Cited: 31
The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic
Maria Karoliny da Silva Torres, Carlos David Araújo Bichara, Maria de Nazaré do Socorro de Almeida, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 30
Design of SARS-CoV-2 Mpro, PLpro Dual-Target Inhibitors Based on Deep Reinforcement Learning and Virtual Screening
Li-chuan Zhang, Huilin Zhao, Jin Liu, et al.
Future Medicinal Chemistry (2022) Vol. 14, Iss. 6, pp. 393-405
Open Access | Times Cited: 28
Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses
Jiajing Li, Yining Wang, Kundan Solanki, et al.
Antiviral Research (2023) Vol. 211, pp. 105555-105555
Open Access | Times Cited: 18
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
Haokun Tian, Changsen Yang, Tiangang Song, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 17
Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial
Bei Wang, Haijun Li, Mi-mi Cai, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102189-102189
Open Access | Times Cited: 15
FORMULATION DEVELOPMENT AND PHARMACOKINETIC STUDIES OF NIRMATRELVIR LOADED SOLID LIPID NANOPARTICLES USING BOX-BEHNKEN DESIGN
S M, S Sangeetha
International Journal of Applied Pharmaceutics (2025), pp. 101-112
Open Access
Page 1 - Next Page

Scroll to top